-
DPP4 is an AR-stimulated tumor suppressor gene that is downregulated during progression to castration-resistant prostate cancer; treatment with DPP4 inhibitors, commonly used to treat type 2 diabetes, may accelerate prostate cancer progression following androgen deprivation therapy
-
The authors provide evidence that DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in the lungs of smokers and chronic obstructive pulmonary disease patients, which could partially explain why these individuals are more susceptible to Middle East respiratory syndrome coronavirus infection.
-
In the light of the downmodulating role of CD26 in major chemokines.
-
DPP4 levels were found to be increased in polycystic ovary syndrome patients compared to controls.
-
Data indicate that lncRNA-OIS1 links oncogenic induction and senescence with the activation of the tumor suppressor DPP4.
-
Constitutive DPP4 activity is positively associated with lean mass, central adiposity, and insulin resistance and negatively to general adiposity.
-
CD26 mRNA expression in rheumatoid arthritis patients is associated with disease activity and bone erosion
-
While in anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis (AAV) patients (n = 29) CD26 was increased on CD4(+) lymphocytes, CD39 and CD73 were generally reduced on patients' T-cells.
-
Serum DPP-IV may be a predictive biomarker for PTC diagnosis and prognosis in Chinese male patients.
-
Low DPP4 expression is associated with microalbuminuria in patients with type 1 diabetes.
-
dipeptidyl peptidase IV (DPP IV) might play role(s) in amyloid formation and is upregulated in Alzheimer's brain neurons and occurs in multiple amyloid plaques.
-
CRABP1, COL11A1, FMO2, PRG4, or C2ORF40. Immunofluorescent staining confirmed that SFRP2 and FMO1 define cell types of dramatically different morphology.
-
DPP-4, besides playing a role in incretin effects, directly affects beta cell function and survival.
-
Plasma levels of DPP4 were decreased in patients with rheumatoid arthritis or systemic sclerosis, compared to controls.
-
Fluctuation in the levels of DPP4 does not play an important role in prognosis, early detection and diagnosis of medullary thyroid cancer.
-
there is a CD26-related linkage with USP22 in Malignant pleural mesothelioma cell inhibition induced by anti-CD26 monoclonal antibody HuCD26mAb
-
Results show a high serum DPP4 activity in hepatocellular carcinoma (HCC) and associated with poor clinical prognosis. Genetic ablation of DPP4 or treatment with its inhibitor (vildagliptin) prevented high-fat diet (HFD)-induced HCC. Also, HFD-induced DPP4 activity facilitated HCC angiogenesis and cancer cell metastasis. These results revealed a link between obesity-related high serum DPP4 activity and HCC progression.
-
Constitutive DPP4 activity was associated with early markers of endothelial proinflammatory activation and microvascular function, and may have an influence and even be influenced by inflammation and microvascular blood flow in subjects with excess body weight without diabetes.
-
Data on CD26/dipeptidyl peptidase IV (CD26)-mediated immune regulation suggest that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders [Review].
-
Study provides mechanistic insights into the molecular interaction between KLK5 and DPP4 as well as CD4+ T cell derived KLK5 mediated enzymatic cleavage of DPP4 from cell surface. Study uncovers a hitherto unknown cellular source and mechanism behind enhanced plasma DPP4 activity in T2DM.